Status: Recruiting
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
Participants needed: 31
Trial details
Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 29, 2026Locations: 1
Eligibility criteria
Participants must have histologically or cytologically confirmed recurrent RAS m... [+16]
Participants who are pregnant or lactating. [+26]